Development of Quality of Life Questionnaire in Gastric Cancers
- Conditions
- Health Condition 1: C169- Malignant neoplasm of stomach, unspecified
- Registration Number
- CTRI/2021/02/031117
- Lead Sponsor
- niversity of Southampton
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Histologically proven as gastric adenocarcinoma with disease stages I-IV (UICC TNM 8th)
2. Patients with a gastric or junction cancer whose epicenter is located within 2 cm of the
oesophagogastric junction
3. Patients receiving treatment(either currently or within the last 12 months) including a systemic
treatment (chemotherapy, target agents, and immunotherapy), surgical resection, and radiotherapy or receiving supportive or palliative care
4. Patients who are willing and able to give fully informed consent to participate
5. Patients who are literate in English or Hindi
1. Patients under 18 years of age
2. Patients with a concurrent malignancy
3. Cancer survivors defined as people who have completed treatment with curative intent more than 12 months ago and are now cancer-free.
4. Patients enrolled in other quality of life studies which will affect the results of the current study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Phase 1: To compile an exhaustive list of relevant QOL issues covering new treatments and different cultural perspectives from 3 sources namely, literature, patients and health care professionals. <br/ ><br>Phase 2: To develop a provisional module and to ensure that the proposed changes are in line with recommended EORTC QLG guidelines.Timepoint: 12 months
- Secondary Outcome Measures
Name Time Method Phase 3: To administer EORTC-QLQ-C30 plus the provisional updated module to patients. <br/ ><br>Phase 4: Field test in large international groups of patientsTimepoint: Day 1 of enrolment into the study